These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35613488)

  • 1. Transitioning from insulin to dipeptidyl-peptidase 4 (DPP-4) inhibitors for type 2 diabetes.
    Hamrick I; Goblirsch MJ; Tuan WJ; Beckham F
    Geriatr Nurs; 2022; 46():86-89. PubMed ID: 35613488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in Hospitalized Patients With Diabetes.
    Petite SE; Hill MC
    Ann Pharmacother; 2021 Nov; 55(11):1326-1332. PubMed ID: 33615832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
    Gillani SW; Moosvi AF
    Curr Pharm Des; 2020; 26(34):4315-4322. PubMed ID: 32268860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
    Tricco AC; Antony J; Khan PA; Ghassemi M; Hamid JS; Ashoor H; Blondal E; Soobiah C; Yu CH; Hutton B; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
    BMJ Open; 2014 Dec; 4(12):e005752. PubMed ID: 25537781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in the Inpatient Setting.
    Petite SE; Hill MC
    J Pharm Pract; 2022 Apr; 35(2):229-234. PubMed ID: 33094657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and a Sulfonylurea in a Real-World Setting.
    Aboubechara N; Ledesma VM; Niu F; Lee SM; Patel YA; Millares M; Hui RL
    Perm J; 2020 Nov; 24():1-8. PubMed ID: 33482956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin.
    Shibuki K; Shimada S; Aoyama T
    J Diabetes Res; 2020; 2020():6321826. PubMed ID: 33224988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta-analysis.
    Zhou X; Shi H; Zhu S; Wang H; Sun S
    J Diabetes Investig; 2022 Mar; 13(3):468-477. PubMed ID: 34551206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake.
    Okada S; Okada K; Okada J; Kikkawa K; Yamada E; Saito T; Andou T; Ohshima K
    Diabetes Metab Syndr; 2023 Jul; 17(7):102806. PubMed ID: 37343509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis.
    Kim YG; Min SH; Hahn S; Oh TJ; Park KS; Cho YM
    Diabetes Res Clin Pract; 2016 Jun; 116():86-95. PubMed ID: 27321321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.
    Hinnen D
    Diabetes Educ; 2015 Dec; 41(1 Suppl):19S-31S. PubMed ID: 26453595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.
    Moore KB; Saudek CD
    Am J Ther; 2008; 15(5):484-91. PubMed ID: 18806525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
    Fadini GP; Albiero M; Menegazzo L; de Kreutzenberg SV; Avogaro A
    Diabetes Obes Metab; 2012 Jun; 14(6):518-22. PubMed ID: 22171692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients.
    Esposito K; Chiodini P; Maiorino MI; Capuano A; Cozzolino D; Petrizzo M; Bellastella G; Giugliano D
    BMJ Open; 2015 Feb; 5(2):e005892. PubMed ID: 25687897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials.
    Esposito K; Chiodini P; Maiorino MI; Bellastella G; Capuano A; Giugliano D
    BMJ Open; 2014 Jun; 4(6):e005442. PubMed ID: 24916090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.